Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Improved MRSI in a Murine Glioma Model Using semiLASER, Refining the Metabolomics Data Obtained from Murine Models

  • Javed, Zoona|||0009-0009-8279-9744
  • Martinez, Gary V.|||0000-0002-6204-8363
  • Mulero-Acevedo, Marta|||0000-0002-3600-8907
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Cabañas Egaña, Miquel|||0000-0003-0104-0197
  • Lope-Piedrafita, Silvia|||0000-0002-8127-6425
Background: Magnetic resonance spectroscopic imaging (MRSI) offers valuable metabolic information for assessing brain tumor progression and therapeutic response, but its performance in rodent models is often hindered by the low signal-to-noise ratio (SNR) and spatially heterogeneous spectral quality, particularly in peripheral voxels. These issues reduce the number of usable spectra available for quantitative and classifier-based analyses. To address this, we implemented a multi-voxel MRSI-semiLASER sequence-widely recommended in clinical practice-on a 7T Bruker Biospec system running ParaVision 5.1 to improve spectral homogeneity in mouse brain tumor studies. Results: Compared with the vendor CSI-PRESS sequence, MRSI-semiLASER produced more uniform spectra across the grid and achieved up to a 1.2-fold SNR increase in murine glioma, enabling a 20% reduction in slice thickness without compromising spectral quality. Importantly, the sequence produced a substantial gain in the proportion of spectra amenable to analysis, particularly in outer grid voxels that frequently fail with CSI-PRESS. The implemented MRSI-semiLASER sequence and instructions are openly available to the community. Conclusions: MRSI-semiLASER improves spectral homogeneity, increases the proportion of usable spectra, and supports higher spatial detail. These technical improvements may enhance data yield per subject and may facilitate future applications such as more robust pattern recognition workflows and greater data efficiency in longitudinal studies, although such aspects were not evaluated here.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous

  • Ungan, Gulnur Semahat|||0000-0002-5436-4665
  • Pons-Escoda, Albert|||0000-0003-4167-8291
  • Ulinic, Daniel|||0009-0006-3318-0839
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Ortega-Martorell, Sandra|||0000-0001-9927-3209
  • Olier, Iván|||0000-0002-5679-7501
  • Vellido, Alfredo|||0000-0002-9843-1911
  • Majos, Carles|||0000-0003-0468-5150
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
The standard treatment in glioblastoma includes maximal safe resection followed by concomitant radiotherapy plus chemotherapy and adjuvant temozolomide. The first follow-up study to evaluate treatment response is performed 1 month after concomitant treatment, when contrast-enhancing regions may appear that can correspond to true progression or pseudoprogression. We retrospectively evaluated 31 consecutive patients at the first follow-up after concomitant treatment to check whether the metabolic pattern assessed with multivoxel MRS was predictive of treatment response 2 months later. We extracted the underlying metabolic patterns of the contrast-enhancing regions with a blind-source separation method and mapped them over the reference images. Pattern heterogeneity was calculated using entropy, and association between patterns and outcomes was measured with Cramér's V. We identified three distinct metabolic patterns-proliferative, necrotic, and responsive, which were associated with status 2 months later. Individually, 70% of the patients showed metabolically heterogeneous patterns in the contrast-enhancing regions. Metabolic heterogeneity was not related to the regions' size and only stable patients were less heterogeneous than the rest. Contrast-enhancing regions are also metabolically heterogeneous 1 month after concomitant treatment. This could explain the reported difficulty in finding robust pseudoprogression biomarkers.